Tags

Type your tag names separated by a space and hit enter

Omega-3 polyunsaturated fatty acids and chronic obstructive pulmonary disease.
Curr Opin Clin Nutr Metab Care. 2015 Mar; 18(2):128-32.CO

Abstract

PURPOSE OF REVIEW

The aim of the present review was to summarize recent research developments relating omega-3 polyunsaturated fatty acids (PUFAs) and chronic obstructive pulmonary disease (COPD).

RECENT FINDINGS

COPD is a chronic inflammatory disease; hence, omega-3 PUFAs may have beneficial effects. At present, however, there are limited data available regarding the potential for omega-3 PUFAs to be used therapeutically in COPD. In 2012-2013, several observational studies have emerged, which demonstrate that circulating omega-3 PUFA levels in COPD are inversely associated with systemic inflammation and positively associated with clinical outcomes. To date, all interventions incorporating omega-3 PUFAs in COPD have used nutrient combinations, such that the specific effects of omega-3 PUFAs cannot be determined. Three clinical trials in COPD are underway, which use therapeutic doses of omega-3 PUFAs alone, with positive results beginning to emerge in 2014.

SUMMARY

Observational data support the hypothesis that omega-3 PUFAs may provide a therapeutic strategy for managing COPD. Several intervention trials using omega-3 PUFAs in COPD are underway, which will provide a substantive amount of new data to inform the field and allow evidence-based advice to be generated for patients with COPD in the near future.

Authors+Show Affiliations

School of Biomedical Sciences and Pharmacy, Centre for Asthma and Respiratory Diseases, Hunter Medical Research Institute, University of Newcastle, NSW, Australia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25581034

Citation

Wood, Lisa G.. "Omega-3 Polyunsaturated Fatty Acids and Chronic Obstructive Pulmonary Disease." Current Opinion in Clinical Nutrition and Metabolic Care, vol. 18, no. 2, 2015, pp. 128-32.
Wood LG. Omega-3 polyunsaturated fatty acids and chronic obstructive pulmonary disease. Curr Opin Clin Nutr Metab Care. 2015;18(2):128-32.
Wood, L. G. (2015). Omega-3 polyunsaturated fatty acids and chronic obstructive pulmonary disease. Current Opinion in Clinical Nutrition and Metabolic Care, 18(2), 128-32. https://doi.org/10.1097/MCO.0000000000000142
Wood LG. Omega-3 Polyunsaturated Fatty Acids and Chronic Obstructive Pulmonary Disease. Curr Opin Clin Nutr Metab Care. 2015;18(2):128-32. PubMed PMID: 25581034.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 polyunsaturated fatty acids and chronic obstructive pulmonary disease. A1 - Wood,Lisa G, PY - 2015/1/13/entrez PY - 2015/1/13/pubmed PY - 2015/9/25/medline SP - 128 EP - 32 JF - Current opinion in clinical nutrition and metabolic care JO - Curr Opin Clin Nutr Metab Care VL - 18 IS - 2 N2 - PURPOSE OF REVIEW: The aim of the present review was to summarize recent research developments relating omega-3 polyunsaturated fatty acids (PUFAs) and chronic obstructive pulmonary disease (COPD). RECENT FINDINGS: COPD is a chronic inflammatory disease; hence, omega-3 PUFAs may have beneficial effects. At present, however, there are limited data available regarding the potential for omega-3 PUFAs to be used therapeutically in COPD. In 2012-2013, several observational studies have emerged, which demonstrate that circulating omega-3 PUFA levels in COPD are inversely associated with systemic inflammation and positively associated with clinical outcomes. To date, all interventions incorporating omega-3 PUFAs in COPD have used nutrient combinations, such that the specific effects of omega-3 PUFAs cannot be determined. Three clinical trials in COPD are underway, which use therapeutic doses of omega-3 PUFAs alone, with positive results beginning to emerge in 2014. SUMMARY: Observational data support the hypothesis that omega-3 PUFAs may provide a therapeutic strategy for managing COPD. Several intervention trials using omega-3 PUFAs in COPD are underway, which will provide a substantive amount of new data to inform the field and allow evidence-based advice to be generated for patients with COPD in the near future. SN - 1473-6519 UR - https://www.unboundmedicine.com/medline/citation/25581034/Omega_3_polyunsaturated_fatty_acids_and_chronic_obstructive_pulmonary_disease_ L2 - http://dx.doi.org/10.1097/MCO.0000000000000142 DB - PRIME DP - Unbound Medicine ER -